- Home
- RVSB vs LUNG Comparison
RVSB vs LUNG Comparison
Compare RVSB & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVSB
- LUNG
- Stock Information
- Founded
- RVSB 1923
- LUNG 1995
- Country
- RVSB United States
- LUNG United States
- Employees
- RVSB N/A
- LUNG N/A
- Industry
- RVSB Savings Institutions
- LUNG Industrial Specialties
- Sector
- RVSB Finance
- LUNG Health Care
- Exchange
- RVSB Nasdaq
- LUNG Nasdaq
- Market Cap
- RVSB 115.6M
- LUNG 124.0M
- IPO Year
- RVSB 1993
- LUNG 2020
- Fundamental
- Price
- RVSB $5.73
- LUNG $2.74
- Analyst Decision
- RVSB Buy
- LUNG Buy
- Analyst Count
- RVSB 1
- LUNG 6
- Target Price
- RVSB $7.00
- LUNG $11.53
- AVG Volume (30 Days)
- RVSB 236.2K
- LUNG 310.5K
- Earning Date
- RVSB 07-24-2025
- LUNG 07-30-2025
- Dividend Yield
- RVSB 1.40%
- LUNG N/A
- EPS Growth
- RVSB 27.97
- LUNG N/A
- EPS
- RVSB 0.23
- LUNG N/A
- Revenue
- RVSB $50,239,000.00
- LUNG $87,473,000.00
- Revenue This Year
- RVSB $12.68
- LUNG $18.02
- Revenue Next Year
- RVSB $11.53
- LUNG $18.17
- P/E Ratio
- RVSB $24.87
- LUNG N/A
- Revenue Growth
- RVSB 3.95
- LUNG 19.84
- 52 Week Low
- RVSB $3.30
- LUNG $2.50
- 52 Week High
- RVSB $6.59
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- RVSB 57.17
- LUNG 39.14
- Support Level
- RVSB $5.47
- LUNG $2.52
- Resistance Level
- RVSB $5.65
- LUNG $2.84
- Average True Range (ATR)
- RVSB 0.17
- LUNG 0.16
- MACD
- RVSB 0.05
- LUNG 0.03
- Stochastic Oscillator
- RVSB 68.52
- LUNG 28.50
About RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.